Chronic Myeloproliferative Disorders

TARIQ I MUGHAL is Professor of Medicine and Haematology/Oncology at the University of Texas Southwestern Medical School, Dallas, USA and Consultant Haematologist at Guy’s & St Thomas’ Hospitals, London UKJOHN M. GOLDMAN is Professor of Haematology at Imperial College London, Hammersmith Hospital, London, UK.

• I. Bcr/Abl Positive Chronic Myeloproliferative Disorders. 1. Epidemiology and history. 2. Cytogenetics and molecular biology. 3. Risk stratification. 4. Clinical features. 5. Non-transplant treatment options. 6. Allogeneic stem cell transplantation. 7. Autologous stem cell transplantation. 8. Vaccines. 9. A therapeutic algorithm and concluding remarks. II. Bcr/Abl Negative Chronic Myeloproliferative Disorders. 10. Epidemiology and history. 11. Cytogenetics and molecular biology. 12. Risk stratification. 13. Clinical features. 14. Non-transplant treatment options. 15. Transplantation options. 16. A therapeutic algorithm and concluding remarks.